From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Dermatology>
  4. Summary and Comment

What Is Severe Psoriasis?

Impact on a patient’s quality of life is more important than skin area in determining disease severity.

All patients with psoriasis would like to rid themselves of it. Some have widespread disease; others have psoriasis only on the scalp or only on the elbows and knees and not elsewhere. Others have a single plaque on the penis. Who has the most severe disease? According to the FDA, severe disease is defined by plaques affecting more than 20% of the total body surface area (BSA). But who is really more severely affected — a patient with psoriasis over 25% of his body who goes about his day undisturbed, in short sleeves and shorts, or a patient with 1% involvement who hides at home and refuses social invitations in shame? In clinical practice, dermatologists routinely take into account the impact of psoriasis on quality of life in determining severity.

Now, a group of experts has validated this concept. In a consensus report, they conclude that physical and mental disabilities should be considered when judging psoriasis severity. Psoriasis affects physical, emotional, social, sexual, and financial aspects of life. Affected patients have trouble sleeping, sitting, walking, and using their hands. They are sad, embarrassed, and burdened with shame. They lose time and income from work and spend time and income on treatments. They don’t date. These patients may need "aggressive therapies," even if only small portions of their skin have psoriasis.

Thus, the consensus group divides psoriatic patients into two "tiers" based on the need for local therapy versus systemic treatments and phototherapy. Candidates for local therapy often have psoriasis involving less than 5% of their BSA. However, some patients affected over less than 5% of their BSA should be candidates for systemic therapy, phototherapy, or both, because of difficulties related to location, coexisting psoriatic arthritis, or impaired physical or mental functioning.

Comment: Psoriasis is not a cosmetic disease. Although the subjectivity involved in placing a patient in one tier or the other may make third-party carriers nervous, this "therapy-based" division of patients reflects the actual circumstances by which dermatologists make treatment decisions and the way patients want to be treated.

— Mark V. Dahl, MD

Published in Journal Watch Dermatology March 16, 2007

Citation(s):

Pariser DM et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007 Feb; 143:239-42.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.